GRFS vs. ALNY, TEVA, GMAB, RPRX, BGNE, BMRN, VTRS, UTHR, RDY, and SRPT
Should you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Alnylam Pharmaceuticals (ALNY), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Grifols (NASDAQ:GRFS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.
Grifols has a net margin of 0.90% compared to Alnylam Pharmaceuticals' net margin of -16.58%. Grifols' return on equity of 1.73% beat Alnylam Pharmaceuticals' return on equity.
Grifols has higher revenue and earnings than Alnylam Pharmaceuticals.
Grifols presently has a consensus target price of $10.50, suggesting a potential upside of 46.65%. Alnylam Pharmaceuticals has a consensus target price of $216.19, suggesting a potential upside of 45.65%. Given Grifols' higher probable upside, research analysts clearly believe Grifols is more favorable than Alnylam Pharmaceuticals.
93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Alnylam Pharmaceuticals received 742 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 55.95% of users gave Grifols an outperform vote.
In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than Grifols. MarketBeat recorded 9 mentions for Alnylam Pharmaceuticals and 2 mentions for Grifols. Alnylam Pharmaceuticals' average media sentiment score of 0.91 beat Grifols' score of 0.68 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.
Grifols has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.
Summary
Alnylam Pharmaceuticals beats Grifols on 8 of the 15 factors compared between the two stocks.
Get Grifols News Delivered to You Automatically
Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
